Abstract
The etiology of Parkinson’s disease (PD) is still unclear, but mutations in PRKN have provided some biological insights. The role of PRKN mutations and other genetic variation in determining the clinical features of PD remains unresolved. The aim of the study was to analyze PRKN mutations in PD and controls in the Polish population and to try to correlate between the presence of genetic variants and clinical features. We screened for PRKN mutations in 90 PD patients and 113 controls and evaluated clinical features in these patients. We showed that in the Polish population 4% of PD patients had PRKN mutations (single or with additional polymorphism) while single heterozygous polymorphisms (S167N, E310D, D394N) of PRKN were present in 21% of sporadic PD. Moreover, 5% PD patients had more than one PRKN change (polymorphisms and mutations). Detected PRKN variants moderately correlated with PD course and response to L-dopa. It also showed that other PARK genes (SNCA, HTRA2, SPR) mutations probably may additionally influence PD risk and clinical features. PRKN variants are relatively common in our Polish series of patients with PD. Analysis of the PRKN gene may be useful in determining clinical phenotype, and helping with diagnostic and prognostic procedures in the future.
Keywords: PARK, PRKN, Genetic variants, Clinical features, Parkinson’s disease.
Current Genomics
Title:Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson’s Disease
Volume: 16 Issue: 4
Author(s): Anna Oczkowska, Jolanta Florczak-Wyspianska, Agnieszka Permoda-Osip, Michal Owecki, Margarita Lianeri, Wojciech Kozubski and Jolanta Dorszewska
Affiliation:
Keywords: PARK, PRKN, Genetic variants, Clinical features, Parkinson’s disease.
Abstract: The etiology of Parkinson’s disease (PD) is still unclear, but mutations in PRKN have provided some biological insights. The role of PRKN mutations and other genetic variation in determining the clinical features of PD remains unresolved. The aim of the study was to analyze PRKN mutations in PD and controls in the Polish population and to try to correlate between the presence of genetic variants and clinical features. We screened for PRKN mutations in 90 PD patients and 113 controls and evaluated clinical features in these patients. We showed that in the Polish population 4% of PD patients had PRKN mutations (single or with additional polymorphism) while single heterozygous polymorphisms (S167N, E310D, D394N) of PRKN were present in 21% of sporadic PD. Moreover, 5% PD patients had more than one PRKN change (polymorphisms and mutations). Detected PRKN variants moderately correlated with PD course and response to L-dopa. It also showed that other PARK genes (SNCA, HTRA2, SPR) mutations probably may additionally influence PD risk and clinical features. PRKN variants are relatively common in our Polish series of patients with PD. Analysis of the PRKN gene may be useful in determining clinical phenotype, and helping with diagnostic and prognostic procedures in the future.
Export Options
About this article
Cite this article as:
Oczkowska Anna, Florczak-Wyspianska Jolanta, Permoda-Osip Agnieszka, Owecki Michal, Lianeri Margarita, Kozubski Wojciech and Dorszewska Jolanta, Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson’s Disease, Current Genomics 2015; 16 (4) . https://dx.doi.org/10.2174/1389202916666150326002549
DOI https://dx.doi.org/10.2174/1389202916666150326002549 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design Pharmacological Therapy of Cushings Syndrome: Drugs and Indications
Mini-Reviews in Medicinal Chemistry Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Current Topics in Medicinal Chemistry Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Improving Red Blood Cell K-Uptake and its Impact on O2/CO2 Exchange, and NO-Generation in Microvascular CHD: A Novel Therapeutic Approach
Recent Patents on Cardiovascular Drug Discovery Pharmacokinetics, Disposition, and Metabolism of [14C]-Nebicapone in Humans
Drug Metabolism Letters Artificial Neural Network (ANN) Based Modelling for D1 Like and D2 Like Dopamine Receptor Affinity and Selectivity
Medicinal Chemistry Immunotherapies for Parkinson’s Disease: Progression of Clinical Development
CNS & Neurological Disorders - Drug Targets Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry Oxidative Stress, Antioxidants and Neurodegenerative Diseases
Current Pharmaceutical Design Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine Treatment of Parkinson’s Disease by MAO-B Inhibitors, New Therapies and Future Challenges - A Mini-Review
Combinatorial Chemistry & High Throughput Screening The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics Advances in Stem Cells Transplantation for the Therapy of Parkinson’s Disease
Current Stem Cell Research & Therapy Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer
CNS & Neurological Disorders - Drug Targets Blocking Receptor Protein Tyrosine Phosphatase β /ζ: A Potential Therapeutic Strategy for Parkinsons Disease
Current Medicinal Chemistry Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs
Current Neuropharmacology